BTAI BioXcel Therapeutics Inc
Company Analysis
Latest News
🔴 BioXcel Therapeutics is trading 6.39% down today in after-hours trading after Chapter 11 filing
BioXcel Therapeutics is trading 6.39% down now at $0.17 in after-hours trading after its August 27, 2026 Chapter 11 filing and proposed court-supervised asset...
🔴 BioXcel Therapeutics is trading 6.12% down today in after-hours trading after Chapter 11 filing
BioXcel Therapeutics is trading 6.12% down at $0.17 after it and its subsidiaries filed for Chapter 11 protection on August 27, 2026. - The proposed...
🔴 BioXcel Therapeutics is trading 74.65% down today after filing for Chapter 11 protection
BioXcel Therapeutics is trading 74.65% down now at $0.18 after the company and subsidiaries filed for Chapter 11 protection on August 27, 2026. - Proposed...
BioXcel Therapeutics Files for Chapter 11 with Teva as Stalking Horse Bidder
BioXcel Therapeutics, Inc. (BTAI) and its subsidiaries filed for Chapter 11 bankruptcy protection on August 27, 2026. In connection with the filing, the...
🔴 BioXcel Therapeutics is trading 60% down in pre-market after filing for Chapter 11 bankruptcy protection
BioXcel Therapeutics is trading 60% down at $0.29 in pre-market after filing for Chapter 11 bankruptcy protection in the United States on August 27, 2026. -...
BioXcel's Earnings Crater Raises a Brutal Question: Can a Sub-Dollar Biotech Survive Its Own Cash Burn?
Shares of BioXcel Therapeutics plunged 9.2% to $0.71 on August 27 after the company reported second-quarter results that missed Wall Street expectations on...
🔴 BioXcel Therapeutics is trading 9.22% down today after second-quarter earnings reported on August 13, 2026
BioXcel Therapeutics reported its second-quarter earnings on August 13, 2026, with an EPS of -$0.49 and revenue of $0.18 million. The stock is currently...
🔴 BioXcel Therapeutics is trading 10.22% down today
BioXcel Therapeutics is trading 10.22% down now at $0.70, with no clearly reported company-specific announcement identified for August 27, 2026; the immediate...
🟢 BioXcel Therapeutics is trading 5% up today after disclosing $1.25 million in additional term loans
BioXcel Therapeutics is trading 5.07% up at $0.78 after disclosing $1.25 million in additional term loans under its August 24, 2026 credit amendment. - The...
🟢 BioXcel Therapeutics is trading 5.7% up in pre-market after disclosing $1.25 million in additional term loans
BioXcel Therapeutics is trading 5.7% up in pre-market at $0.78 after disclosing $1.25 million in additional term loans under its August 24, 2026 credit...
🔴 BioXcel Therapeutics is trading 5.6% down today after $1.25 million financing, $250,000 fee
BioXcel Therapeutics is trading 5.6% down at $0.72 after announcing a fourteenth credit-agreement amendment on August 24, 2026. - The company secured $1.25...
BioXcel Therapeutics Amends Credit Agreement for $1.25M Loan and Modified Covenants
BioXcel Therapeutics, Inc. has entered into a fourteenth amendment to its credit agreement, securing an additional $1.25 million in term loans. The amendment,...
🔴 BioXcel Therapeutics is trading 5.9% down today after extending liquidity-event deadline
BioXcel Therapeutics is trading at $0.76, down -5.86%, after extending its liquidity-event deadline. - On August 24, BioXcel Therapeutics amended its credit...
BioXcel Therapeutics Amends Credit Agreement, Extends Key Transaction Deadline
BioXcel Therapeutics has entered into the Thirteenth Amendment to its Credit Agreement, extending a crucial deadline for the company to secure a strategic...
🟢 BioXcel Therapeutics is trading 6.25% up in pre-market after Q2 earnings beat and positive SERENITY At-Home data
BioXcel Therapeutics is trading at $0.85 (+6.25%) after recent positive Q2 2026 earnings and reinforced confidence from late-stage SERENITY At-Home data. •...
🟢 BioXcel Therapeutics is trading 5.46% up in after-hours trading after positive late-stage at-home agitation-treatment data
BioXcel Therapeutics is trading 5.46% up at $0.85 in after-hours trading after positive late-stage data for its at-home agitation treatment strengthened...
🟢 BioXcel Therapeutics is trading 5.5% up today after positive late-stage data for at-home agitation treatment
BioXcel Therapeutics is trading 5.5% up at $0.84 after positive late-stage data for its at-home agitation treatment strengthened confidence in the company’s...
BioXcel's Promising Drug Data Meets a Looming Debt Deadline — Can Science Outrun Insolvency?
Shares shifted as BioXcel Therapeutics surged 11.3% to $0.89 after positive late-stage clinical trial results for its at-home agitation treatment bolstered...
🟢 BioXcel Therapeutics is trading 11.33% up in pre-market after positive Phase 3 SERENITY At-Home data
BioXcel Therapeutics is trading 11.33% up at $0.89 in pre-market after investors responded to positive Phase 3 SERENITY At-Home data presented on August 19,...
🟢 BioXcel Therapeutics is trading 5.6% up in pre-market after positive Phase 3 SERENITY At-Home data
BioXcel Therapeutics is trading 5.6% up now at $0.87 after investors responded to positive Phase 3 SERENITY At-Home data presented on August 19, 2026. -...